Search Results

Stratasys Ltd. (Nasdaq: SSYS) (“Stratasys” or the “Company”), a leader in polymer 3D printing solutions, has shared that the University Hospital Birmingham in England is delivering improved outcomes for head and neck cancer patients.

Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility.

The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise, delivers light directly to the site of the injury.

Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at its New York City and Birmingham, Alabama, sites.

University of Birmingham spinout Linear Diagnostics, which specialises in near-patient diagnostics for sexually transmitted diseases, has received funding to finesse a point-of-care test for rapid diagnosis of gonorrhoea and Chlamydia in men who have sex with men, and women who have sex with women.

Prapela, Inc., an infant health company in Biddeford, ME, was awarded a grant through the National Institutes of Health (NIH) Blueprint MedTech program and National Institute on Drug Abuse (NIDA), to support the development and evaluation of Prapela’s pad to treat apnea in preterm newborns in collaboration with neonatologists at Tufts Medical Center and the University of Alabama at Birmingham.

During a late-breaking abstract presentation at the annual 2024 NKF Spring Clinical Meetings tomorrow Dr. Dana Rizk, from the University of Alabama at Birmingham Medical Center, will present data on the impact and safety of Fabhalta in the treatment of patients with IgA nephropathy also known as Berger disease.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.